Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907615 · ClinicalTrials.gov registry record · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Shanghai Henlius Biotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
- 2
- Study locations
NCT06907615: Recruiting Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Shanghai Henlius Biotech.
NCT06907615 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Shanghai Henlius Biotech. The registered enrollment target is 243 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06907615, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Shanghai Henlius Biotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Primary Outcome
Objective response rate (ORR) (assessed by the Independent Radiology Review Committee \[IRRC\] as per RECIST v1.1).
Conditions Studied
Interventions
- DRUG HLX43 DOSE 1 (2.0 mg/kg)
- DRUG HLX43 DOSE 2 (2.5 mg/kg)
Study Locations (2)
Texas
- MD Anderson Cancer Hospital - Houston
Beijing Municipality
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2028-06-04 |
| Phase | Phase 2 |
What NCT06907615 shows while recruiting
NCT06907615 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which HLX43 DOSE 1 (2.0 mg/kg) is the first listed.
NCT06907615 reports a single indexed study location in Texas, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT06907615 about?
NCT06907615 is a clinical study titled "A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)". The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
What is the current status of trial NCT06907615?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2025-06-09. Estimated completion is 2028-06-04.
What conditions does trial NCT06907615 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06907615?
The interventions under investigation include: HLX43 DOSE 1 (2.0 mg/kg) (DRUG), HLX43 DOSE 2 (2.5 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT06907615?
This trial is sponsored by Shanghai Henlius Biotech, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06907615 being conducted?
This trial has 2 study locations across Texas, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06907615's enrollment target sits among peer trials
243 151st of 454 higher than 303 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI